-
Jamie Vardy channel to broadcast Bundesliga games
-
King Harald, 'symbol' of Norway, dead at 89
-
STARCARES Completes Basketball Court Revamp in the Philippines, Benefiting Nearly 20,000 People
-
Norway's new King Haakon, popular face of shaken monarchy
-
Norway's new Queen Mette-Marit, a fairytale beset by woe
-
Most stocks rise as attention turns to Warsh speech
-
Nepal orders rescuers to safety as overflow brings new flood risks
-
Japanese rugby U-turns on limits on naturalised players
-
Norway's King Harald V, unifying force who weathered family storms
-
Norway's King Harald dead at 89
-
Australia's McKeown vows to reclaim backstroke world records
-
Climate change hits trout and salmon in UK's prized chalk streams
-
Boston Legacy FC Delays White Stadium Debut to 2028
-
Škoda Octavia Marks 30 Years With Nearly 7.9 Million Units Produced
-
Cancer fears stalk Kosovo's coal heartland
-
Nepal seeking to reach survivors in tunnel as risk of new floods rises
-
Gladys Knight to Reduce Tour Schedule Amid Health Concerns
-
Anger in Austria over business park on former Nazi camp site
-
Galápagos Coral Fossils Reveal Global Warming Intensifies El Niño Cycles
-
In shadow of Premier League, Serie A flexes financial muscle
-
Springboks 'old guard' seek revenge over All Blacks
-
Tanker pays record $5.3 mn to transit Panama Canal: administrator
-
'Find your own room': Japan says can't handle added Asian Games numbers
-
Pilgrims seeking peace caught in deadly Nepal-Tibet floods
-
Fresh flood warnings for disaster-hit Nepal and Tibet, 1,400 still missing
-
China's help critical, but unlikely, for US to choke off Iran
-
Most Asian stocks advance as attention turns to Warsh speech
-
US court rules Pentagon ban of Anthropic unlawful
-
US mother's child murder trial puts spotlight on postpartum psychosis
-
In Zambia, a Shaolin Temple offers a softer face of China
-
'End of an era': Players lament decline of the disc at Gamescom
-
Messi's Inter Miami appoint new coach Gonzalez
-
Air traffic controllers left early before deadly NY crash: report
-
Clashes in Spain's Ceuta month after mass migrant influx
-
Guardian Metal Resources PLC Announces Total Voting Rights
-
Starting Over in a New City: Steps to Take in the First Year
-
Tocvan Announces New Surface Mineralization in Several Zones at Gran Pilar Gold-Silver Project
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - August 28
-
Caledonia Mining Corporation Plc: Maiden Mineral Resource Estimate at Motapa 379,000 oz Measured and Indicated; 131,000 oz Inferred
-
Caledonia Mining Corporation Plc: Blanket Mine Underground Measured and Indicated Mineral Resources Estimate Increases by 22% to 2.18 Million Ounces and Declaration of a Surface Mineral Resource Estimate
-
Golf media firm loses Callaway, PGA Tour deals over violent ad
-
Argentina names unchanged side for Australia Test
-
US to push economic pressure on Iran at G20 finance talks
-
Australia's Lee leads PGA Tour Championship
-
Kiss rotates Wallabies forwards for Argentina Test
-
US judge urged to rebuff restoring Trump name to Kennedy Center
-
Guns, drugs and car chases: GTA 6 preview lands on Netflix after leaks
-
Trump orders Lake Ontario to be renamed 'Lake America'
-
Arteta braced for 'tough' Martinelli, Jesus exits from Arsenal
-
Raphinha, Lopez strike again as Barca beat Athletic
Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026
DENVER, CO / ACCESS Newswire / January 13, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, announced today that Josh Disbrow, Chief Executive Officer of Aytu, will participate in a fireside chat moderated by Thomas Flaten, Senior Research Analyst at Lake Street Capital Markets, at the Lytham Partners 2026 Investor Healthcare Summit.
The webcast will take place at 5:00 p.m. Eastern time on Thursday, January 15, 2026. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/hc2026/ or directly at https://lythampartners.com/hc2026/aytu. A replay will also be available through the same links.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to delivering the Company's medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visit aytubio.com or follow us on LinkedIn.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
[email protected]
Robert Blum
Lytham Partners
[email protected]
SOURCE: Aytu BioPharma, Inc.
View the original press release on ACCESS Newswire
A.Clark--AT